...mos and the 1-year OS was 67.6%. Beside alopecia in all pts, major grade 3-4 toxicities consisted of: anemia 4%, neutrop...
...mos if score ≤2 vs. 14 mos if score >2 (p=0.003). By ACE-27, MS was 19 mos if score 0-1 vs. 12 mos if score 2 or 3 (p=0....
...mos due to behavioral changes. Immune responses were elicited in Pts 1 (PR1 vaccine+PEG-IFN-α), and 3 (PR1 vaccine). Dat...
...mos.,69 pts were accrued between 12/21/04 and 7/20/06. 5 were ineligible; 3 never started treatment. Of the remaining 61...
...mos. for BCRx and 46.4/8.1 for non-BCRx respectively. The survival of BCRx pts was superior at 5 years (7.78% vs. 2%, p ...
...mos (parotid, ovarian, and anal squamous cell CA). Mean % change in SUVmax from baseline for those treated with RAD001 d...
...mos (range 2-16+mos). Median OS in the 22 pts was 7+ mos. (range1-16+ mos) and 12+ mos. (range 2-16+) in pts with clinic...
...mos. CD80 was upregulated in blasts, and CTLA4 was downregulated in CD4+T cells and NK cells in all pts. post-therapy. P...
...mos without progression after last platinum regimen), measurable (by RECIST) recurrent ovarian, peritoneal, or fallopian...
...MOS Social Support (MOS). Overall QOL and long-term physical, mental, and sexual effects were compared between the early...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
